The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
Dr. Elias on Androgen Receptor Inhibitors in HER2-Positive Breast Cancer
August 4th 2015Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.
Dr. Chagpar on Sequencing Therapies for HER2-Positive Breast Cancer
August 3rd 2015Anees B. Chagpar, MD, MA, MPH, MBA, FRCS(C), FACS, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses sequencing therapies for patients with HER2-positive breast cancer.
Neoadjuvant Pertuzumab Regimen Approved in Europe for HER2-Positive Early Breast Cancer
The European Commission has approved the combination of pertuzumab, trastuzumab, and chemotherapy as a neoadjuvant therapy for adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer who are at high risk of recurrence.
Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast Cancer
July 29th 2015Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the research that led to the FDA approval of neoadjuvant pertuzumab as part of a combination regimen for patients with HER2-positive breast cancer.
Everolimus Activity Linked With PIK3CA/PTEN Status in HER2-Positive Breast Cancer
PIK3CA mutations and low/no expression of PTEN correlated with an extension in progression-free survival for patients with metastatic HER2-positive breast cancer treated with the combination of everolimus, trastuzumab, and paclitaxel.
Dr. Esteva Discusses T-DM1 in HER2-Positive Breast Cancer
June 22nd 2015Francisco J. Esteva, MD, PhD, professor, Department of Medicine, associate director, Clinical Investigation Perlmutter Cancer Center, director, Breast Medical Oncology Program, NYU Langone Medical Center, discusses the efficacy of T-DM1 in patients with HER2-positive breast cancer.